From a financial standpoint, the oral-calcitonin program was* immaterial for NVS but highly consequential for EMIS, who is another biotech that can’t seem to do anything right.
*I’m using the past tense deliberately.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”